Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Idioma: | |
| Publicado em: |
Zenodo
2026
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.5281/zenodo.20284207 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Sumário:
- <p class="MsoNormal"><span>Prostate cancer remains one of the leading causes of cancer-related mortality among men worldwide. Although several treatment strategies are available, their clinical effectiveness is often limited by problems such as androgen resistance, adverse side effects, and frequent disease recurrence. In recent years, herbal bioactive compounds have attracted considerable attention because of their low toxicity and ability to act on multiple molecular targets. Exploring the molecular basis of their anticancer activity is important for identifying new therapeutic candidates and supporting translational research. This review aims to critically examine the therapeutic relevance of herbal bioactives against prostate cancer, with particular emphasis on their molecular mechanisms and network pharmacology-based evidence. Relevant literature was collected from databases including PubMed, Scopus, Web of Science, Google Scholar, TCMSP, and IMPPAT up to 2025.Studies were screened according to PRISMA guidelines, and only articles reporting molecular targets, pathway mechanisms, docking, or network pharmacology insights were included. The analysis highlights several phytochemicals—such as quercetin, kaempferol, curcumin, resveratrol, ellagic acid, berberine, and epigallocatechin gallate—that regulate key oncogenic pathways. Frequently modulated molecular targets include AKT1, AR, TP53, CASP3, STAT3, and BCL2, while enriched pathways involve PI3K–Akt, apoptosis, androgen receptor signaling, and cell-cycle regulation. Network pharmacology and docking studies demonstrate strong binding affinities and multi-node regulatory capacity of these bioactives, supporting their therapeutic promise. In conclusion, herbal bioactives offer substantial potential for the development of multi-target therapeutics against prostate cancer. Future research should emphasize mechanistic validation, Nano-formulations for targeted delivery, and well-designed clinical trials to accelerate translation into </span></p>